Yao Reina, Chiu Connie G, Strugnell Scott S, Gill Sabrina, Wiseman Sam M
a St Paul's Hospital, Department of Surgery, University of British Columbia, C303-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
b St Paul's Hospital, Division of Endocrinology/Department of Medicine, University of British Columbia, C486-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Expert Rev Endocrinol Metab. 2011 Mar;6(2):215-243. doi: 10.1586/eem.11.9.
It has long been known that the incidence of thyroid cancer in women is significantly higher than that in men. The objective of this article is to review gender differences in thyroid cancer, as well as epidemiological, clinical and experimental research on the role of sex hormones, their receptors and other molecular factors in this well-established thyroid cancer gender discrepancy. Although more common in women, thyroid cancer typically presents at a more advanced stage and with a worse disease prognosis in men. Clinical evidence on the impact of estrogen and other sex hormones on thyroid cancer has remained inconclusive, although numerous experimental studies have suggested that these hormones and their receptors may play a role in tumorigenesis and tumor progression. Studies of thyroid cancer cell lines suggest that an imbalance between the two estrogen receptor (ER) isoforms, α and β, may be responsible for the cell proliferation seen with estrogen treatment. Expression studies on thyroid tumors indicate that they express ER and possibly progesterone receptors and androgen receptors, but there is conflicting evidence as to whether or not there is a difference in receptor status between thyroid cancers, benign thyroid lesions and normal thyroid tissue. There have been few studies evaluating the ERα/ERβ profiles in thyroid tumors and normal thyroid tissue. Our understanding of the underlying basis for sex differences in thyroid cancer has improved over the last few decades, but the relationship between gender and thyroid cancer risk has remained elusive. Areas for future research include ERα/ERβ profiling of normal and neoplastic thyroid tissue, association between ER status and tumor dedifferentiation, and evaluation of the signaling pathways by which estrogen and other sex steroids exert their effects on thyroid cancer cells. Sex steroid receptors, and then downstream signaling pathways, represent promising future therapeutic targets for thyroid cancer treatment, and further study is required.
长期以来,人们一直知道女性甲状腺癌的发病率显著高于男性。本文的目的是综述甲状腺癌中的性别差异,以及关于性激素、其受体和其他分子因素在这种已确定的甲状腺癌性别差异中所起作用的流行病学、临床和实验研究。虽然甲状腺癌在女性中更常见,但男性甲状腺癌通常在更晚期出现,且疾病预后更差。尽管大量实验研究表明雌激素和其他性激素及其受体可能在肿瘤发生和肿瘤进展中起作用,但关于雌激素和其他性激素对甲状腺癌影响的临床证据仍不明确。对甲状腺癌细胞系的研究表明,两种雌激素受体(ER)亚型α和β之间的失衡可能是雌激素治疗后细胞增殖的原因。对甲状腺肿瘤的表达研究表明,它们表达ER,可能还表达孕激素受体和雄激素受体,但关于甲状腺癌、良性甲状腺病变和正常甲状腺组织之间受体状态是否存在差异,存在相互矛盾的证据。评估甲状腺肿瘤和正常甲状腺组织中ERα/ERβ谱的研究很少。在过去几十年里,我们对甲状腺癌性别差异潜在基础的理解有所改善,但性别与甲状腺癌风险之间的关系仍然难以捉摸。未来的研究领域包括正常和肿瘤性甲状腺组织的ERα/ERβ谱分析、ER状态与肿瘤去分化之间的关联,以及评估雌激素和其他性类固醇对甲状腺癌细胞发挥作用的信号通路。性类固醇受体以及随后的下游信号通路是甲状腺癌治疗未来有前景的治疗靶点,需要进一步研究。